Photocure ASA · OSL:PHO
Photocure ASA — DNB's 6th Annual Health Care Conference 2015
21 slides from Photocure ASA's conference presentation, Dec 15, 2015
Slide 1: Photocure ASA, DNB's 6th Annual Health Care Conference
PHOTOCURE ASA DNB’S 6TH ANNUAL HEALTH CARE CONFERENCE DECEMBER 15, 2015
Slide 2: Disclaimer
Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Photocure ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These statements are based on various as
Slide 3: Investment Highlights
Investment Highlights • World leader in photodynamic technology – Hexvix® commercialized globally – Robust product pipeline • Growing in-market sales +17% LTM 3Q2015 at NOK 204 MNOK – Driven by Hexvix®/Cysview® for improved detection of bladder cancer and patient management – Significant Hexvix /Cys
Slide 4: Creating Value: Diverse Product Portfolio
Creating Value Diverse Product Portfolio Phase Phase Phase Indication Market Status 1 2 3 Optical imaging Marketed as adjunct to white light agent for cystoscopy Hexvix® (EU) improved Cysview® (US) bladder cancer Phase 3 trial for expansion to detection and surveillance market initiated management T
Slide 5: Hexvix/Cysview
Hexvix/Cysview First significant advance for the improved detection and management of bladder cancer in >50 years
Slide 6: Bladder Cancer: Prevalent, Recurring, Progressing and Expensive
Bladder Cancer Prevalent, Recurring, Progressing and Expensive • 5th most common cancer type ‒ Most expensive cancer: $96-187K/patient1 ‒ > 200,000 new patients annually ‒ 75% of patients diagnosed with NMIBC2 • Key therapeutic aim is to avoid progression from NMIBC to muscle invasive disease ‒ ~ 6
Slide 7: Hexvix/Cysview Medical Benefits Validated
Hexvix/Cysview Medical Benefits Validated WLC • Landmark Meta-Analysis published in European Urology (2013)1 Hexvix/Cysview – significantly improves the detection of bladder BLC cancer – reduces the risk of recurrence • Continued positive data flow fuels forward momentum – World Journal of Urology (
Slide 8: Hexvix/Cysview: A Significant Global Specialty Brand
Hexvix/Cysview A Significant Global Specialty Brand • Value of in-market sales of Hexvix/Cysview Global in-market unit sales (by Q) increased YoY 19% year to date to NOK 204 million LTM • Hexvix/Cysview global in-market volume increased YoY 8% in the quarter, and 7% year to date • Overall franchise
Slide 9: Hexvix/Cysview Future Growth Drivers
Hexvix/Cysview Future Growth Drivers • Volume growth in existing markets – Increased penetration in the US – Incorporation in national guidelines (EU & US); publication of expert opinions • Expand into new markets – Surveillance following initial diagnosis represents significant opportunities – Posi
Slide 10: Cevira
Cevira Novel treatment for HPV related diseases of the cervix
Slide 11: Cevira: Addressing Unmet Needs in Cervical Disease
Cevira1 Addressing Unmet Needs in Cervical Disease • Oncogenic Human Papilloma Virus (HPV) is a highly prevalent sexually transmitted disease • Well established cause of Cervical Intraepithelial Neoplasia (CIN) and cervical cancer – Close association of HPV induced cell changes and invasive cancer –
Slide 12: Cevira: A Major Opportunity
CEVIRA A Major Opportunity • Breakthrough single use and fully integrated drug-device technology to satisfy high need for novel therapies to treat global epidemic of HPV/CIN populations • A well tolerated non-systemic treatment option for patients which preserves fertility and avoids the morbidities
Slide 13: Cevira: Significant Sales Potential
CEVIRA Significant Sales Potential • Large patient population based on biopsy confirmed histology of HSIL • ~1M cases HSIL annually in US & West EU1,2 detected through routine cervical screening programs; 50% of these are caused by HPV strain 16 or 183 • ~30% risk of progress to cervical cancer4 • U
Slide 14: Visonac
Visonac Novel non-antibiotic treatment of acne
Slide 15: Visonac: First Photodynamic Treatment for Inflammatory Acne
Visonac1 First Photodynamic Treatment for Inflammatory Acne • Late Stage Development Compound – Phase 3 ready – Development and regulatory risks significantly reduced • High Market Need – Current treatment options, antibiotics and isotretinoin, hampered by possible development of antibiotic resistan
Slide 16: Visonac: Strong Phase 2b Results
Visonac Strong Phase 2b Results • Solid Phase 2b results – Significant reduction in inflammatory lesions – Overall improvement in acne severity – Well tolerated regimen • Ready for Phase 3 registration trials – Clinical Phase 3 program in place and SPA obtained from FDA • Patent coverage across majo
Slide 17: Visonac: Significant Sales Potential
Visonac Significant Sales Potential • $900M USD Market in Moderate- Severe Acne – Dermatologists are main prescriber of oral antibiotics and retinoids • Visonac positioned as second line alternative – Over 2M patients in need of second line treatment options (U.S. and EU) – Favorable risk profile co
Slide 18: Financials
Our mission ts to unprove Fj nancials patient care and quality of li J by making solutions based on photodynamic technology accessible to patients and consumers worldwide PHOTOCURE®
Slide 19: Results by Segment, Third Quarter 2015
Results by Segment Third Quarter 2015 MNOK Q3 '15 Q3 '14 YTD '15 YTD '14 LTM • Commercial franchise: Commercial Franchise – Continued improvement in Total revenues 35,9 26,1 100,2 72,2 126,2 revenues and EBIT Gross profit 33,9 24,5 94,0 67,1 118,2 – EBIT margin year to date at Operating expenses -24
Slide 20: Outlook
Our mission ts to unprove Outlook patient care and qualits of li J by making solutions based on photodynamic technology accessible to patients and consumers worldwide PHOTOCURE®
Slide 21: Outlook
Outlook • Hexvix/Cysview global in-market unit sales growth of 10% in 2015 FINANCIAL • Initiate necessary documentation for the Cevira device to ensure readiness for the Phase 3 trial following the SPA approval CLINICAL • Reporting of clinical results of Hexvix/Cysview phase 3 market expansion study
Photocure — DNB's 6th Annual Health Care Conference 2015 on 6ix